Diligence memo · auto-generated · as of July 2, 2026

Satellos Bioscience Inc.

Satellos Bioscience Inc. looks fair against its niche peers and is quiet on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Satellos Bioscience Inc. operates in Biotechnology, based in TORONTO.

Sub-sector tags: biotech.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Satellos Bioscience Inc. has raised $64M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $33M on 2023-05-10.

Most recent recorded round closed around 2024-12-20.

Valuation (modeled)modeled

Provath models Satellos Bioscience Inc. at approximately $146M (range $50M–$239M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.87× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era. Within the normal band (87% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 26 months.

Last raise 18 mo ago; this sector typically re-raises about every 14 months.

Slightly overdue versus sector cadence.

The last round was 1.3× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 85% of Biotechnology peers (4293 compared).

Modeled value ranks above 66% of those peers.

Closest niche peers: Mt McKinley Medical Holding Corp USA, YAP Therapeutics Inc, Pinteon Therapeutics, Inc., OncXerna Therapeutics, Ltd., EpiBiologics, Inc..

Peoplefiled

24 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.